Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY News - liver fibrosis

MedXY AI/MedXY News/Tag: liver fibrosis

MedXY News

EnglishTag

liver fibrosis

26 all articles · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial immunotherapy heart failure obesity atrial fibrillation cardiovascular risk Cardiology biomarkers clinical trials Hypertension oncology public health critical care artificial intelligence breast cancer Alzheimer's disease diabetes cardiovascular disease type 1 diabetes nutrition chronic kidney disease

Latest news

Tag

Global Variability in Non-Invasive Testing Accuracy for MASLD: Key Findings from the G-MASLD Study

Gastroenterology

Global Variability in Non-Invasive Testing Accuracy for MASLD: Key Findings from the G-MASLD Study

By MedXY|Jul 16, 2026

The G-MASLD study evaluated the diagnostic accuracy of non-invasive fibrosis tests across 41 countries, revealing regional variability and identifying Agile-3+ and Agile-4 as the most accurate for advanced fibrosis and cirrhosis in MASLD pa

Unraveling Hepatitis B-Induced Liver Fibrosis: The Critical Role of Pyruvate, PPARα, and Reactive Oxygen Species

Gastroenterology

Unraveling Hepatitis B-Induced Liver Fibrosis: The Critical Role of Pyruvate, PPARα, and Reactive Oxygen Species

By MedXY|Jul 10, 2026

This article explores the mechanism by which HBV induces liver fibrosis through pyruvate-dependent ROS production and PPARα inhibition, highlighting novel therapeutic targets for chronic hepatitis B management.

Decoding Liver Fibrosis in MASLD: AI-Derived Collagen Phenotypes Enhance Molecular and Clinical Insights

Gastroenterology

Decoding Liver Fibrosis in MASLD: AI-Derived Collagen Phenotypes Enhance Molecular and Clinical Insights

By MedXY|Jun 25, 2026

This article explores a novel AI framework that identifies distinct collagen deposition patterns in MASLD, offering improved molecular specificity and prognostic value beyond traditional fibrosis assessments.

Validated Early Detection Metrics Could Narrow Liver Fibrosis Screening Without Losing Clinical Signal

Gastroenterology

Validated Early Detection Metrics Could Narrow Liver Fibrosis Screening Without Losing Clinical Signal

By MedXY|Jun 19, 2026

A validation study suggests current liver fibrosis screening criteria are too broad. A refined risk-based approach reduced eligibility from 60–76% to 10–22% of adults while improving the yield of elevated liver stiffness and predicting futu

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH

Clinical Updates

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH

By MedXY|Apr 2, 2026

This review synthesizes the evolving landscape of noninvasive tests (NITs) in MASH, detailing their role as surrogate endpoints for adverse outcomes and therapeutic response based on recent clinical trials and meta-analyses.

Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy

Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy

By MedXY|Mar 31, 2026

This study identifies the integrin αV-YAP-CTGF axis in liver sinusoidal endothelial cells as a primary driver of fibrosis and carcinogenesis in congestive hepatopathy. By targeting this mechanosensitive pathway, researchers demonstrated a s

Targeting the Integrin αV-YAP-CTGF Axis: A New Frontier in Treating Congestive Hepatopathy and Liver Carcinogenesis

Targeting the Integrin αV-YAP-CTGF Axis: A New Frontier in Treating Congestive Hepatopathy and Liver Carcinogenesis

By MedXY|Mar 28, 2026

Researchers have identified a mechanosensitive signaling pathway in liver sinusoidal endothelial cells that drives fibrosis and cancer in response to chronic congestion, offering a new therapeutic target for heart-failure-related liver dise

From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy

From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy

By MedXY|Mar 28, 2026

Researchers have identified a novel signaling pathway in liver sinusoidal endothelial cells (LSECs) that drives fibrosis and liver cancer in congestive hepatopathy. The study highlights the Integrin αV-YAP-CTGF axis as a critical mechanism

Mechanotransduction in Congestive Hepatopathy: The Integrin αV-YAP-CTGF Axis as a Driver of Fibrosis and Carcinogenesis

Clinical Updates

Mechanotransduction in Congestive Hepatopathy: The Integrin αV-YAP-CTGF Axis as a Driver of Fibrosis and Carcinogenesis

By MedXY|Mar 18, 2026

This review synthesizes recent findings on how mechanical stress in congestive hepatopathy activates the Integrin αV-YAP-CTGF pathway in liver sinusoidal endothelial cells, leading to fibrosis and liver cancer.

Metabolic Synergy: How Obesity and Diabetes Amplify Liver Disease Risk in Alpha-1 Antitrypsin Deficiency

Gastroenterology

Metabolic Synergy: How Obesity and Diabetes Amplify Liver Disease Risk in Alpha-1 Antitrypsin Deficiency

By MedXY|Mar 13, 2026

A large-scale longitudinal study reveals that obesity and diabetes synergistically amplify the risk of advanced liver disease in individuals with Alpha-1 Antitrypsin Deficiency (AATD), while also identifying a complex relationship between b

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

Gastroenterology

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

By MedXY|Feb 17, 2026

The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the main finding

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial

Gastroenterology

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial

By MedXY|Feb 16, 2026

The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial

Diabetes & Endocrinology

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial

By MedXY|Jan 10, 2026

The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transfo

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data

Diabetes & Endocrinology

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data

By MedXY|Nov 23, 2025

A target-trial emulation of 4,476 matched T2DM patients with early MASLD found GLP-1RA use was associated with a 25% lower hazard of progression to high-risk FIB‑4 versus DPP‑4i (HR 0.75); no difference was seen for hard liver outcomes.

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

Diabetes & Endocrinology

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

By MedXY|Nov 17, 2025

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑intermed

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

Diabetes & Endocrinology

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

By MedXY|Nov 14, 2025

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoint

Enhancing Prognostication in Chronic Liver Disease: The Role of Liver Corrected T1 and Magnetic Resonance Elastography in Real-World Clinical Practice

Gastroenterology

Enhancing Prognostication in Chronic Liver Disease: The Role of Liver Corrected T1 and Magnetic Resonance Elastography in Real-World Clinical Practice

By MedXY|Oct 29, 2025

This study highlights the complementary utility of liver corrected T1 (cT1) and magnetic resonance elastography (MRE) for predicting chronic liver disease progression, emphasizing the critical prognostic role of disease activity beyond fibr

Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis

Gastroenterology

Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis

By MedXY|Oct 28, 2025

Claudin-1 is upregulated in primary sclerosing cholangitis (PSC), promoting biliary fibrosis and cholestasis. Preclinical models show that Claudin-1-specific monoclonal antibodies reduce liver injury and fibrosis, highlighting a promising t

Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts

Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts

By MedXY|Oct 28, 2025

Hypertension independently worsens clinical outcomes and liver fibrosis progression in MASLD, highlighting the need for integrated cardiovascular and hepatic care.

Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial

Gastroenterology

Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial

By MedXY|Oct 28, 2025

The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted th

Ask MedXY AI

Most popular

Clinical Updates

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Family Medicine & Nutrition

The Curious Scent of Feces: The Dual Identity and Health Secrets of Skatole

Initiation, Adherence, and Persistence to Guideline-Directed Medical Therapy After Heart Failure Hospitalization: Bridging the Gap Between Prescription and Sustained Use

Family Medicine & Nutrition

How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk

ACOG Endorses Updated 2026 Cervical Cancer Screening Guidelines: Key Changes and Implications